Table I.
Lesion information | VLD-RT (n = 51) | SD-RT (n = 37) | P value* | ||
---|---|---|---|---|---|
Lesion diagnosis, n (%) | .1912 | ||||
pcMZL | 34 (66.7) | 17 (48.6) | |||
pcFCL | 17 (33.3) | 18 (51.4) | |||
NOS | 0 | 2 (0.05) | |||
Location, n (%) | .5184 | ||||
Head | 15 (29.4) | 17 (46.0) | |||
Trunk | 21 (41.2) | 8 (21.6) | |||
Extremities | 15 (29.4) | 12 (32.4) | |||
Lesion size (cm) | .0145 | ||||
N | 33 | 27 | |||
Range | 0.2–6.0 | 0.2–14.0 | |||
Median | 1.0 | 3.0 | |||
Duration of follow-up ( years) | .0271 | ||||
Range | 0.02–12.6 | 0.2–18.8 | |||
Median | 3.9 | 7.0 | |||
Immediate side effects, n (%) | <.0001 | ||||
No | 43 (84.3) | 8 (21.6) | |||
Yes | |||||
Erythema | 8 (15.7) | 5 | 29 (78.4) | 22 | |
Itch | 1 | 2 | |||
Fatigue | 1 | 2 | |||
PIH | 1 | 0 | |||
Erythema and fatigue | 0 | 1 | |||
Itch and fatigue | 0 | 1 | |||
Pain and fatigue | 0 | 1 | |||
Long-term side effects (>6 months), n (%) | .0036 | ||||
None | 47 (92.2) | 22 (59.5) | |||
Yes | |||||
PIH | 4 (7.8) | 2 | 15 (40.5) | 9 | |
Hair loss | 2 | 4 | |||
Pain | 0 | 1 | |||
PIH and hair loss | 0 | 1 | |||
CR, n (%) | .4937 | ||||
No | |||||
No response | 3 (5.9) | 0 | 1 (2.7) | 1 | |
PR | 2 | 0 | |||
PR with recurrence | 1 | 0 | |||
Yes | |||||
CR | 48 (94.1) | 39 | 36 (97.3) | 25 | |
CR with in-field occurrence of new lesions | 5 | 2 | |||
CR with out-of-field occurrence of new lesions | 0 | 8 | |||
CR with relapse of same lesions | 4 | 1 |
CR, Complete response; NOS, not otherwise specified; pcFCL, primary cutaneous follicle center lymphoma; pcMZL, primary cutaneous marginal zone lymphoma; PIH, postinflammatory hyperpigmentation; PR, partial response; SD-RT, standard dose radiation therapy; VLD-RT, very low-dose radiation therapy.
Obtained from generalized repeated measures linear models with the appropriate link function based on the distribution of the lesion characteristic. Continuous measures were transformed when their distributions were skewed.